articleNatureJul 24, 2020HYBRID OA

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

LRLaura RivaSYShuofeng YuanXYXin YinLMLaura Martin‐SanchoNMNaoko Matsunaga

Sanford Burnham Prebys Medical Discovery Institute · Discovery Institute · +18 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

And the cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825 and ONO 5334. Notably, MDL-28170, ONO 5334 and apilimod were found to antagonize viral replication in human pneumocyte-like cells derived from induced pluripotent stem cells, and apilimod also demonstrated antiviral efficacy in a primary human lung explant model. Since most of the molecules identified in this study have already advanced into the clinic, their known pharmacological and human safety profiles will enable accelerated preclinical and clinical evaluation of these drugs for the treatment of COVID-19.

Citation impact

856
total citations
FWCI
18.91
Percentile
100%
References
68
Citations per year

Authors

45

Topics & keywords

Topics
Keywords
  • Drug repositioning
  • Repurposing
  • Medicine
  • Drug discovery
  • Pharmacology
  • Coronavirus
  • Viral replication
  • Drug
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding